drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (anti-HER2)
drug_description
A humanized anti-HER2 monoclonal antibody that binds HER2 domain IV, inhibits signaling, and mediates ADCC.
nci_thesaurus_concept_id
C1647
nci_thesaurus_preferred_term
Trastuzumab
nci_thesaurus_definition
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous, Subcutaneous
drug_mechanism_of_action
Humanized monoclonal antibody targeting HER2 that binds domain IV on the HER2 receptor, inhibiting HER2-driven signaling (e.g., PI3K/AKT/MAPK) and preventing receptor activation/shed extracellular domain; its Fc engages immune effector cells via Fcγ receptors to mediate antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
drug_name
Trastuzumab
nct_id_drug_ref
NCT06276868